Gohara Shunsuke, Yoshida Ryoji, Kawahara Kenta, Sakata Junki, Arita Hidetaka, Nakashima Hikaru, Kawaguchi Sho, Nagao Yuka, Yamana Keisuke, Nagata Masashi, Hirosue Akiyuki, Hiraki Akimitsu, Nakayama Hideki
Department of Oral and Maxillofacial Surgery, Faculty of Life Sciences, Kumamoto University, Kumamoto 860-8556, Japan.
Section of Oral Oncology, Department of Oral and Maxillofacial Surgery, Fukuoka Dental College, Fukuoka 814-0193, Japan.
Mol Clin Oncol. 2021 Oct;15(4):209. doi: 10.3892/mco.2021.2372. Epub 2021 Aug 9.
gene mutations can lead to mutant p53 protein accumulation in cancer cells, thereby inducing the production of serum antip53 antibodies (Ap53Ab) in patients with various types of cancer. The aim of the present study was to re-evaluate the clinicopathological and prognostic significance of Ap53Ab using the Ap53Ab ELISA kit, approved by the Japanese Health Insurance System in 2007. Ap53Ab was measured as a tumor marker in 94 patients with oral squamous cell carcinoma (OSCC), by subjecting paraffin-embedded sections obtained from biopsy specimens to immunohistochemical analysis to confirm p53 expression. The associations among Ap53Ab status, p53 expression and clinical significance in OSCC were examined. A total of 23% of the patients were Ap53Ab-positive. Ap53Ab status was found to be significantly associated with p53 expression status in primary tumors (P=0.027), clinical T-category, pathological N-category and pathological stage (P=0.04, P=0.010 and P=0.013, respectively). Kaplan-Meier curve analysis revealed that Ap53Ab status was significantly associated with poor disease-free survival (DFS; P=0.043), and Cox regression analysis revealed that Ap53Ab status was a significant prognostic factor for DFS in patients with OSCC (hazard ratio=2.807; 95% confidence interval: 1.029-7.160; P=0.044). These results suggested that Ap53Ab measurement may reflect the p53 mutation status and an aggressive malignant phenotype, and it may serve as a useful predictive marker candidate for OSCC in clinical practice.
基因突变可导致癌细胞中突变型p53蛋白积累，从而在各类癌症患者中诱导产生血清抗p53抗体（Ap53Ab）。本研究旨在使用2007年获日本医保系统批准的Ap53Ab ELISA试剂盒，重新评估Ap53Ab的临床病理及预后意义。对94例口腔鳞状细胞癌（OSCC）患者的石蜡包埋切片进行免疫组化分析以确认p53表达，从而将Ap53Ab作为肿瘤标志物进行检测。研究了OSCC中Ap53Ab状态、p53表达与临床意义之间的关联。共有23%的患者Ap53Ab呈阳性。发现Ap53Ab状态与原发肿瘤中的p53表达状态（P=0.027）、临床T分类、病理N分类及病理分期显著相关（分别为P=0.04、P=0.010和P=0.013）。Kaplan-Meier曲线分析显示，Ap53Ab状态与无病生存期（DFS）差显著相关（P=0.043），Cox回归分析显示，Ap53Ab状态是OSCC患者DFS的显著预后因素（风险比=2.807；95%置信区间：1.029 - 7.160；P=0.044）。这些结果表明，检测Ap53Ab可能反映p53突变状态及侵袭性恶性表型，在临床实践中它可能是OSCC有用的预测标志物候选。
